Ponalrestat
CAS: 72702-95-5
Ref. 3D-FP102755
1g | Descatalogado | ||
10mg | Descatalogado | ||
25mg | Descatalogado | ||
50mg | Descatalogado | ||
100mg | Descatalogado | ||
250mg | Descatalogado | ||
500mg | Descatalogado |
Información del producto
- Ponalrestat [USAN:INN:BAN]
- 1-Phthalazineacetic acid, 3-((4-bromo-2-fluorophenyl)methyl)-3,4-dihydro-4-oxo-
- 3-(4-Bromo-2-fluorobenzyl)-3,4-dihydro-4-oxo-1-phthalazineacetic acid
- Ici 128,436
- Ponalrestatum
- Ponalrestatum [Latin]
- Unii-2Cv0A5G64E
- [3-(4-Bromo-2-Fluorobenzyl)-4-Oxo-3,4-Dihydrophthalazin-1-Yl]Acetic Acid
Ponalrestat is a drug that has been developed to treat metabolic disorders, such as diabetic neuropathy. It inhibits the breakdown of glucose by the enzyme glucosidase, thereby improving insulin sensitivity and reducing glucose levels in blood. Ponalrestat is an inhibitor drug that prevents the breakdown of glucose by inhibiting enzymes called glucosidases. It does this by forming an ester linkage with a high value and biocompatible polymer. The active forms are hydrolyzed by esterases or glucuronidases to release ponalrestat's active form, which then binds to the receptor site on the target enzyme and inhibits its activity. Ponalrestat has been shown to improve locomotor activity in mice with papillary muscle dysfunction.